Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Oral Manifestations of Sickle Cell Disease
source: British Dental Journal
year: 2019
authors: Chekroun M, Chérifi H, Fournier B,Gaultier F, Sitbon IY,Ferré FC,Gogly B
summary/abstract:Sickle cell disease is one of the most common autosomal recessive genetic diseases. It gives rise to abnormally shaped red blood cells with altered function, the primary clinical features being haemolytic anaemia and vascular occlusion. Acute complications are frequent and variable and include chest syndrome, stroke, infection mainly due to asplenia, bone pain and priapism. Other chronic complications which can occur are bone necrosis, nephropathy and heart, lung and skin disorders. Oral lesions are also very common and include aseptic pulp necrosis, mucosal damage due to anaemia, fungal infections due to numerous antibiotic therapies, dental eruption delays, bone pain and osteomyelitis of the maxilla, and oral neuropathies, including of the mental nerve of the chin.
The oral care of sickle cell patients requires specific precautions such as good management of local anaesthetics, rigorous anti-infective prophylaxis as well as controlled prescription of analgesics. Regular oral follow-up of sickle cell patients is necessary.
organization: Paris-Descartes University, France; Laboratory of Molecular Oral Pathophysiology, France; Paris-Diderot University, FranceDOI: 10.1038/sj.bdj.2019.4
read more full text
+myBinderRelated Content
-
First systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
Signs of Sickle Cell in Your EyesSickle cell disease is a blood disorder ...
-
Medical Resource use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claim...Background: The study investigated the ...
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
A multiple drug approach to preventing sickle cell crisisSickle cell disease is characterized by ...
-
Roland B. Scott Memorial Symposium: I Want Somebody to LoveRoland B. Scott Symposium on Sickle Cell...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.